ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,626,626 | +17.9% | 133,602 | +33.5% | 0.04% | +8.3% |
| Q2 2023 | $3,076,472 | -9.9% | 100,113 | +5.7% | 0.04% | -21.7% |
| Q1 2023 | $3,412,972 | -1.0% | 94,739 | +8.6% | 0.05% | -4.2% |
| Q4 2022 | $3,447,799 | +2.6% | 87,275 | +4.4% | 0.05% | -2.0% |
| Q3 2022 | $3,361,000 | +5.7% | 83,618 | +10.6% | 0.05% | +53.1% |
| Q2 2022 | $3,179,000 | +8.0% | 75,577 | 0.0% | 0.03% | +33.3% |
| Q1 2022 | $2,944,000 | +91.4% | 75,577 | +95.9% | 0.02% | +100.0% |
| Q4 2021 | $1,538,000 | +10.3% | 38,574 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $1,394,000 | – | 38,574 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |